Biocon Pharma’s acquisition of an FDA approval for a generic drug substance on April 28, 2026, is anticipated to expand its United States market footprint and drive future top-line growth as the company continues to scale its commercial portfolio.
Biocon Pharma’s acquisition of an FDA approval for a generic drug substance on April 28, 2026, is anticipated to expand its United States market footprint and drive future top-line growth as the company continues to scale its commercial portfolio.